RESEARCH TRIANGLE PARK, N.C.
and WESTLAKE VILLAGE, Calif.,
Oct. 16, 2018 /PRNewswire/
-- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind
Corporation (Nasdaq: MNKD) today announced the closing of their
pending worldwide exclusive license and collaboration agreement for
the development and commercialization of Treprostinil
Technosphere®, a dry powder formulation of treprostinil
being developed for the treatment of pulmonary arterial
hypertension. As previously announced, the effectiveness of the
agreement was conditioned upon expiration or termination of the
required waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act. The requisite waiting period expired on
October 15, 2018, and the agreement
became effective the same day.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with diseases such as diabetes and pulmonary arterial hypertension.
MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company's first FDA-approved
product and the only inhaled rapid-acting mealtime insulin in
the United States, where it is
available by prescription from pharmacies nationwide. MannKind is
headquartered in Westlake Village,
California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a
balanced, value-creating biotechnology model. We are confident in
our future thanks to our fundamental attributes, namely our
obsession with quality and innovation, the power of our brands, our
entrepreneurial culture and our bioinformatics leadership. We also
believe that our determination to be responsible citizens – having
a positive impact on patients, the environment and society – will
sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we
are focused on addressing the acute national shortage of
transplantable lungs and other organs with a variety of
technologies that either delay the need for such organs or expand
the supply. Lung Biotechnology is the first public benefit
corporation subsidiary of a public biotechnology or pharmaceutical
company. [uthr‑g]
Forward-looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although United
Therapeutics' and MannKind's management teams believe that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of United Therapeutics and MannKind, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA,
regarding whether and when to approve any drug or device
application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that
could affect the availability or commercial potential of such
product candidates, the absence of any guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives as well
as those discussed or identified in the public filings with the
Securities and Exchange Commission made by United Therapeutics and
MannKind, including those risks and uncertainties listed in United
Therapeutics' and MannKind's annual reports on Form 10-K for the
year ended December 31, 2017, and
listed or described in subsequent reports filed by United
Therapeutics and MannKind with the Securities and Exchange
Commission. We are providing this information as of October 16, 2018, and neither United Therapeutics
nor MannKind undertake any obligation to update or revise the
information contained in this press release whether as a result of
new information, future events or any other reason.
TECHNOSPHERE and AFREZZA are registered trademarks of MannKind
Corporation.
View original
content:http://www.prnewswire.com/news-releases/united-therapeutics-and-mannkind-announce-closing-of-license-and-collaboration-agreement-300731458.html
SOURCE United Therapeutics Corporation